What Is Asherman's Syndrome?
Asherman's syndrome (also called intrauterine adhesions, intrauterine synechiae, or uterine synechiae) is a condition in which bands of scar tissue (adhesions) form within the uterine cavity. These adhesions can range from thin, filmy bands to dense, fibrous tissue that binds the walls of the uterus together, reducing or eliminating the functional endometrial cavity.
The adhesions replace the normal endometrium -- the nutrient-rich lining that thickens each month to support embryo implantation. When adhesions occupy a significant portion of the cavity, the remaining endometrium may be insufficient to support menstruation or sustain a pregnancy.
Prevalence
Asherman's syndrome is more common than many people realise, but its true prevalence is difficult to determine because many women are asymptomatic:
- General prevalence: Estimated at 1.5-2% of women of reproductive age
- After D&C for miscarriage: Adhesions develop in approximately 15-20% of cases
- After D&C for retained placenta (postpartum): Adhesion rate may be as high as 25-30%
- After repeated D&C procedures: Risk increases substantially -- up to 30-40% after two or more procedures
- In infertile populations: Found in approximately 5-7% of women undergoing hysteroscopy as part of infertility evaluation
In India, the prevalence may be higher than global estimates due to the additional burden of genital tuberculosis, which is an important non-surgical cause of intrauterine adhesions.
Key Takeaway
Asherman's syndrome is an acquired condition -- it develops after damage to the uterine lining. The single most common cause is uterine curettage (D&C), particularly when performed after a miscarriage or delivery. If you have had a D&C and now experience lighter or absent periods, Asherman's syndrome should be considered.
Causes and Risk Factors
Asherman's syndrome results from damage to the basal layer of the endometrium -- the deep layer from which the functional endometrium regenerates each month. When this layer is destroyed over a significant area, the opposing raw surfaces of the uterine walls heal by forming adhesions rather than regenerating normal endometrium.
Dilatation and Curettage (D&C) -- The Most Common Cause
D&C performed on the recently pregnant uterus accounts for approximately 90% of all cases of Asherman's syndrome. The uterus is particularly vulnerable to adhesion formation during and shortly after pregnancy because the endometrium is soft, thick, and easily disrupted.
- D&C after incomplete miscarriage: Most common single cause -- adhesions develop in 15-20% of cases
- D&C for retained products of conception after delivery: Even higher risk (25-30%), especially if performed more than 48 hours postpartum
- Repeated D&C procedures: Risk is cumulative -- each subsequent procedure increases the likelihood of adhesion formation
- D&C after induced abortion: Similar risk profile to post-miscarriage D&C
The risk is highest when curettage is performed in the presence of infection or when vigorous scraping damages the basal endometrial layer.
Uterine Surgery
Surgical procedures involving the uterine cavity can damage the endometrium and trigger adhesion formation:
- Myomectomy (fibroid removal): Particularly hysteroscopic myomectomy for submucous fibroids, or open myomectomy that enters the uterine cavity
- Caesarean section: Especially if complicated by infection
- Uterine artery embolisation: For fibroid treatment -- can compromise endometrial blood supply
- Endometrial ablation: Deliberately destroys the endometrium (performed for heavy bleeding in women who do not wish to conceive)
Genital Tuberculosis -- A Major Cause in India
Genital tuberculosis is a critically important cause of Asherman's syndrome in India and other TB-endemic countries. India carries approximately 27% of the global TB burden, and genital TB affects an estimated 5-19% of infertile women in India, depending on the population studied and diagnostic methods used.
TB reaches the genital tract via the bloodstream (haematogenous spread) from a primary pulmonary focus -- which may have occurred years earlier and may even have been subclinical. The endometrium is affected in approximately 60-80% of genital TB cases.
TB endometritis causes:
- Granulomatous inflammation that destroys the endometrium
- Dense intrauterine adhesions that are often more extensive and difficult to treat than post-surgical adhesions
- Endometrial fibrosis with a thin, scarred lining that may not regenerate even after adhesiolysis
- A "shrunken" or "frozen" uterine cavity in advanced cases
Infection and Inflammation
Non-TB infections can also damage the endometrium:
- Postpartum endometritis: Infection of the uterine lining after delivery
- Pelvic inflammatory disease: Ascending infection from the cervix
- Schistosomiasis: Relevant in some regions, though uncommon in India
- IUD-related infection: Rare with modern copper or hormonal IUDs
Risk Factors Summary
| Risk Factor | Estimated Adhesion Risk |
|---|---|
| Single D&C after first-trimester miscarriage | 15-20% |
| Two or more D&C procedures | 30-40% |
| D&C for retained placenta (postpartum) | 25-30% |
| Genital tuberculosis | Variable; often severe |
| Hysteroscopic myomectomy | 5-10% (with adhesion prevention) |
| Caesarean section with infection | Low-moderate |
Warning
If you have had a D&C (for miscarriage, retained placenta, or any other reason) and subsequently notice that your periods have become significantly lighter or have stopped, consult your gynaecologist. Early detection of adhesions allows simpler treatment with better outcomes.
Warning
In India, genital TB should be actively investigated in any woman with intrauterine adhesions, particularly if there is no clear history of uterine surgery. Endometrial biopsy with TB-PCR is the most sensitive diagnostic test. A full course of anti-tubercular treatment (ATT) must be completed before any surgical intervention for adhesions.
Classification: Severity of Asherman's Syndrome
The severity of intrauterine adhesions is classified based on the extent of cavity involvement, the type of adhesions, and the impact on menstruation. Several classification systems exist, but the most widely used are the European Society of Gynaecological Endoscopy (ESGE) classification and the American Fertility Society (AFS) classification (now the ASRM classification).
Mild (Grade I)
- Adhesions: Thin, filmy adhesions involving less than one-quarter of the cavity
- Type: Mostly endometrial (soft, easily separated)
- Menstruation: Normal or slightly reduced flow
- Tubal ostia: Both visible and unobstructed
- Prognosis: Excellent -- pregnancy rates after treatment approach 70-80%
Moderate (Grade II)
- Adhesions: Fibromuscular adhesions involving one-quarter to three-quarters of the cavity
- Type: Partially fibrotic, some endometrial component
- Menstruation: Noticeably reduced (hypomenorrhea) or irregular
- Tubal ostia: One or both partially occluded
- Prognosis: Good -- pregnancy rates after treatment approximately 50-60%
Severe (Grade III)
- Adhesions: Dense, fibrous adhesions involving more than three-quarters of the cavity, or complete obliteration
- Type: Predominantly connective tissue (dense, difficult to separate)
- Menstruation: Absent (amenorrhea) or only spotting
- Tubal ostia: Both blocked by adhesions
- Prognosis: Guarded -- pregnancy rates after treatment approximately 20-40%, often requiring multiple procedures
Key Takeaway
The severity of Asherman's syndrome is the single most important predictor of fertility outcomes after treatment. Mild disease has excellent prognosis, while severe disease requires more intensive treatment and carries a lower but still meaningful chance of pregnancy.
Symptoms
The symptoms of Asherman's syndrome depend on the extent and location of adhesions. Some women have no symptoms at all, while others experience significant menstrual and reproductive disturbances.
Hypomenorrhea (Light Periods)
The most common symptom. Periods become noticeably lighter and shorter than before the causative event (surgery or infection). This occurs because adhesions replace the endometrium -- less functional lining means less menstrual bleeding.
Amenorrhea (Absent Periods)
Complete absence of menstruation despite having functional ovaries and normal hormonal levels. This occurs when adhesions obliterate the cavity or block the cervical canal. The ovaries continue to cycle normally -- the woman ovulates each month but has nowhere for the shed endometrium to exit.
Cyclic Pelvic Pain
Some women experience monthly pelvic pain at the expected time of menstruation despite having no visible period. This occurs when adhesions block the outflow of menstrual blood, causing haematometra (blood collecting in the uterus) or retrograde menstruation.
Infertility
Adhesions impair fertility through multiple mechanisms:
- Reduced endometrial surface for embryo implantation
- Physical obstruction of the cervical canal or tubal ostia, preventing sperm transport
- Impaired endometrial blood flow to the remaining lining
- Distorted cavity architecture that cannot accommodate a growing pregnancy
Recurrent Pregnancy Loss
Women with partial adhesions may conceive but experience repeated miscarriages due to:
- Insufficient endometrial support for the developing placenta
- Restricted cavity expansion as the pregnancy grows
- Abnormal placentation (the placenta implants on or near adhesions with poor blood supply)
When to Seek Evaluation
Consult your gynaecologist if you experience:
- Lighter or absent periods after a D&C, uterine surgery, or any uterine procedure
- Inability to conceive after 6-12 months of trying
- Cyclic pelvic pain with no visible period
- Two or more miscarriages
- Any menstrual change following a uterine procedure
Key Takeaway
The hallmark presentation of Asherman's syndrome is lighter or absent periods after a uterine procedure. If your periods changed after a D&C or surgery, do not assume this is normal -- ask your doctor to evaluate for intrauterine adhesions.
Light Periods (Hypomenorrhea)
Noticeably lighter and shorter periods following a D&C or uterine procedure — the most common symptom
Absent Periods (Amenorrhea)
Complete absence of menstruation despite normal ovarian function — occurs when adhesions obliterate the cavity
Cyclic Pelvic Pain
Monthly pelvic cramping at the expected time of menstruation without visible bleeding, due to trapped menstrual blood
Infertility
Adhesions reduce endometrial surface for implantation and may block sperm transport or tubal ostia
Recurrent Pregnancy Loss
Repeated miscarriages from insufficient endometrial support, restricted cavity, or abnormal placentation
Often Asymptomatic
Some women with mild adhesions have normal periods and discover the condition only during infertility workup
Diagnosis
Accurate diagnosis of Asherman's syndrome requires evaluating the uterine cavity directly or through imaging. The condition cannot be diagnosed by blood tests or external physical examination alone.
Hysteroscopy -- The Gold Standard
Office or operative hysteroscopy is the definitive diagnostic method. A thin telescope (hysteroscope) is inserted through the cervix to directly visualise the uterine cavity:
- Adhesions are seen directly -- their extent, type, and density can be assessed
- Tubal ostia are evaluated for patency
- The amount of remaining normal endometrium is assessed
- Diagnostic and therapeutic simultaneously -- adhesions can be divided during the same procedure
- Cost in India: Rs 10,000-30,000 (diagnostic); Rs 30,000-1,00,000 (operative)
Hysterosalpingography (HSG)
An outpatient X-ray procedure that can suggest Asherman's syndrome:
- Findings: Irregular filling defects within the uterine cavity, "moth-eaten" appearance, or complete failure of contrast to enter the cavity
- Limitations: Cannot determine adhesion severity or type; cannot distinguish adhesions from polyps or small fibroids
- Useful as a screening test but cannot replace hysteroscopy for definitive diagnosis
- Cost in India: Rs 3,000-8,000
Saline Infusion Sonohysterography (SIS / Sono-HSG)
Transvaginal ultrasound performed while saline is instilled into the uterine cavity:
- Better than standard ultrasound for detecting adhesions
- Shows "bridging bands" within the fluid-filled cavity
- More accessible than hysteroscopy, less invasive
- Cost in India: Rs 2,000-5,000
Transvaginal Ultrasound
Standard 2D or 3D ultrasound may show:
- A thin endometrial stripe despite being in the proliferative or secretory phase
- Discontinuity of the endometrial lining
- Haematometra (retained blood) if cervical adhesions block outflow
- Limited sensitivity for mild adhesions
- Cost in India: Rs 1,000-3,000
MRI
Occasionally used for complex cases:
- Demonstrates the extent of adhesions and remaining endometrium
- Useful when hysteroscopy is technically difficult
- May detect haematometra not visible on ultrasound
- Cost in India: Rs 5,000-15,000
TB Workup (Essential in India)
For all Indian women with intrauterine adhesions, particularly if there is no clear surgical cause:
- Endometrial biopsy with TB-PCR: Most sensitive test for genital TB
- Endometrial histopathology: Look for granulomas (caseating or non-caseating)
- GeneXpert on endometrial tissue: Rapid molecular test
- Chest X-ray: Assess for pulmonary TB (past or present)
- Mantoux test / IGRA: Supportive evidence of TB exposure
- Cost: Rs 2,000-8,000 for TB-PCR; Rs 500-1,500 for Mantoux; Rs 3,000-5,000 for GeneXpert
Key Takeaway
Hysteroscopy is the gold standard for diagnosing Asherman's syndrome -- it allows both diagnosis and treatment in the same sitting. In India, always include TB testing as part of the evaluation, especially when adhesions have no clear surgical cause.
Clinical Suspicion
Lighter or absent periods following D&C, uterine surgery, or genital TB — or unexplained infertility with thin endometrium
Hysteroscopic Confirmation
Direct visualisation of intrauterine adhesions via hysteroscopy — the gold standard for diagnosis and severity grading
Severity Classification
Graded as mild, moderate, or severe based on extent of cavity involvement, adhesion type, and menstrual impact (ESGE/ASRM)
TB Exclusion (India)
Endometrial biopsy with TB-PCR to rule out genital tuberculosis as the underlying cause — essential in the Indian context
Standard Diagnostic Tests in India
- Hysteroscopy (Gold Standard) — Direct visualisation of adhesions — allows simultaneous diagnosis, grading, and treatment in the same sitting
- Hysterosalpingography (HSG) — X-ray dye test showing irregular filling defects or 'moth-eaten' cavity pattern — useful screening but cannot determine severity
- Saline Infusion Sonohysterography (SIS) — Ultrasound with saline contrast reveals bridging bands within the uterine cavity — more accessible than hysteroscopy
- Transvaginal Ultrasound — May show a thin endometrial stripe or haematometra — limited sensitivity for mild adhesions but widely available
- Endometrial TB-PCR / GeneXpert — Molecular testing on endometrial biopsy for genital tuberculosis — critical in India where TB is a significant cause
Treatment: Hysteroscopic Adhesiolysis
The primary treatment for Asherman's syndrome is hysteroscopic adhesiolysis -- surgical division of intrauterine adhesions using a hysteroscope. The goal is to restore a normal-sized uterine cavity lined with functional endometrium.
The Procedure
- Anaesthesia: Usually general anaesthesia or sedation; mild cases may be treated under local anaesthesia in an office setting
- Cervical dilation: The cervix is gently dilated to allow passage of the hysteroscope
- Cavity visualisation: The hysteroscope is inserted and the cavity is distended with fluid (saline or glycine) to allow visualisation
- Adhesion division: Adhesions are carefully divided using:
- Hysteroscopic scissors (preferred for mild-moderate adhesions -- less thermal damage)
- Electrosurgical resection (for dense, fibrous adhesions)
- Laser (available in select centres)
- Cavity assessment: After adhesiolysis, the surgeon confirms that both tubal ostia are visible and the cavity has been restored to a near-normal shape
- Concurrent ultrasound guidance: Recommended for severe cases to prevent uterine perforation
Duration and Recovery
- Procedure duration: 20-60 minutes depending on severity
- Hospital stay: Usually day-case (discharge same day)
- Recovery: Most women resume normal activities within 2-3 days
- Return to fertility treatment: Typically 2-3 months after surgery
Outcomes by Severity
| Severity | Adhesion Recurrence | Menstruation Restored | Pregnancy Rate |
|---|---|---|---|
| Mild (Grade I) | 10-15% | 90-95% | 70-80% |
| Moderate (Grade II) | 20-30% | 75-85% | 50-60% |
| Severe (Grade III) | 40-60% | 50-60% | 20-40% |
Repeat Procedures
Adhesion recurrence is a significant challenge, particularly in severe cases. Many women require two or three hysteroscopic procedures to achieve an adequate cavity. A second-look hysteroscopy is typically performed 1-2 months after the initial surgery to assess the cavity and divide any recurrent adhesions.
Key Takeaway
Hysteroscopic adhesiolysis is the standard treatment for Asherman's syndrome. Success depends on severity -- mild cases have excellent outcomes, while severe cases often require multiple procedures and adjunctive therapies.
Post-Surgical Management: Preventing Adhesion Recurrence
Preventing adhesion recurrence after surgery is as important as the surgery itself. Several strategies are used in combination to promote endometrial regeneration and prevent the raw surfaces from re-adhering.
Oestrogen Therapy
High-dose oestrogen supplementation is routinely prescribed after adhesiolysis to stimulate endometrial growth and cover the raw surfaces with regenerating endometrium:
- Typical regimen: Conjugated oestrogen 2.5 mg twice daily or estradiol valerate 4-6 mg/day for 4-8 weeks
- Followed by: Medroxyprogesterone acetate or micronised progesterone to induce withdrawal bleeding
- Purpose: Rapid endometrial proliferation to reduce recurrence
Intrauterine Balloon / IUD Placement
A physical barrier is placed inside the uterine cavity immediately after surgery to prevent the opposing walls from adhering while the endometrium heals:
- Foley catheter balloon: A paediatric Foley catheter is inserted and the balloon inflated with 3-5 mL saline -- kept in place for 7-14 days
- Intrauterine balloon stent: Purpose-designed devices (e.g., Cook balloon) are available
- Copper IUD: Placed for 2-3 months as a spacer device
- Evidence: Balloon placement reduces recurrence rates from 40-50% to approximately 15-25% in severe cases
Hyaluronic Acid Gel
Anti-adhesion barriers containing cross-linked hyaluronic acid (e.g., Hyalobarrier gel) are instilled into the cavity after surgery:
- Creates a temporary physical and chemical barrier between the uterine walls
- Biodegrades within 7-14 days
- Some studies show a 20-30% reduction in adhesion recurrence
- Cost: Rs 5,000-15,000 per application
Amnion Grafting (Emerging Therapy)
Human amniotic membrane grafts placed inside the uterus after adhesiolysis are an emerging approach for severe cases:
- The amnion contains growth factors that promote endometrial regeneration
- Studies from India and China show promising results in reducing recurrence in severe Asherman's
- Available at select tertiary centres in India
Second-Look Hysteroscopy
A follow-up hysteroscopy performed 4-8 weeks after the initial procedure:
- Assesses healing and identifies recurrent adhesions early
- Any recurrent adhesions can be divided at this stage (usually milder than initial adhesions)
- Considered standard of care for moderate and severe Asherman's syndrome
- Some specialists perform two or three follow-up procedures for severe disease
Key Takeaway
Post-surgical management is critical to preventing adhesion recurrence. The combination of oestrogen therapy, intrauterine balloon placement, and second-look hysteroscopy offers the best outcomes.
Fertility Outcomes After Treatment
Fertility outcomes depend primarily on the initial severity of adhesions, the amount of functional endometrium remaining, and the underlying cause.
By Severity Grade
Mild Asherman's (Grade I):
- Menstruation restored in 90-95% of women
- Pregnancy rate: 70-80% after adhesiolysis
- Live birth rate: 60-70%
- Most women conceive within 12 months of treatment
- Usually requires only one surgical procedure
Moderate Asherman's (Grade II):
- Menstruation restored in 75-85% of women
- Pregnancy rate: 50-60% after adhesiolysis
- Live birth rate: 40-50%
- May require 1-2 procedures with adjunctive therapy
- Conception may take 12-18 months
Severe Asherman's (Grade III):
- Menstruation restored in 50-60% of women
- Pregnancy rate: 20-40% after adhesiolysis
- Live birth rate: 15-30%
- Often requires 2-3 procedures and extensive post-operative management
- Higher rates of pregnancy complications even when conception occurs
Pregnancy Complications in Asherman's Patients
Even after successful adhesiolysis, women with a history of Asherman's syndrome face increased risks during pregnancy:
- Placenta accreta spectrum: 10-15% risk (abnormally adherent placenta) -- significantly higher than general population (0.1-0.3%)
- Preterm birth: Increased risk due to compromised endometrial support
- Intrauterine growth restriction: From suboptimal placental development
- Cervical incompetence: If cervical adhesions were present
- Recurrent miscarriage: If inadequate endometrial regeneration
TB-Related Asherman's: A Cautionary Note
Genital TB-related Asherman's syndrome carries a poorer prognosis than post-surgical adhesions because:
- TB destroys the basal endometrial layer more extensively
- Endometrial fibrosis may be irreversible even after adhesiolysis and ATT
- The endometrium may remain thin (<7 mm) despite oestrogen therapy
- Dense, extensive adhesions are more likely to recur after surgery
Studies from Indian centres report pregnancy rates of 10-25% in women with TB-related Asherman's, compared to 50-70% for post-surgical adhesions of similar severity.
Warning
If you become pregnant after treatment for Asherman's syndrome, ensure your obstetrician is aware of your history. Close monitoring for placenta accreta is essential -- this condition can cause life-threatening haemorrhage at delivery if not anticipated.
IVF with Asherman's Syndrome
When natural conception does not occur after adhesiolysis, or when the endometrium remains suboptimal, IVF may be considered.
Considerations Before IVF
- Cavity must be optimised: Hysteroscopic adhesiolysis and restoration of an adequate cavity must precede IVF
- Endometrial thickness: A minimum thickness of 7-8 mm is generally needed for embryo transfer. Many Asherman's patients struggle to achieve this
- Endometrial receptivity: Even with adequate thickness, the quality and blood flow of the regenerated endometrium may be compromised
Strategies to Improve Endometrial Preparation
- Extended oestrogen supplementation: Prolonged or higher-dose oestrogen protocols
- Sildenafil (vaginal): Improves uterine blood flow and endometrial thickness in some women
- Granulocyte colony-stimulating factor (G-CSF): Intrauterine infusion may improve endometrial growth (limited evidence)
- Platelet-rich plasma (PRP): Intrauterine infusion of autologous PRP -- emerging evidence from Indian centres shows promise for thin endometrium
- Freeze-all strategy: Freeze all embryos and wait for optimal endometrial preparation in a subsequent cycle
When the Endometrium Cannot Support Pregnancy
In severe cases where the endometrium remains persistently thin (<6 mm) or inadequate despite all interventions:
- Gestational surrogacy: Using a gestational carrier may be the most realistic path to biological parenthood. In India, altruistic surrogacy is regulated under the Surrogacy (Regulation) Act, 2021
- Uterine transplantation: An experimental procedure performed at very few centres worldwide -- not currently available in India for this indication
IVF Success Rates with Asherman's
IVF success rates in Asherman's patients vary widely depending on endometrial quality:
- Adequate endometrium (>7 mm) after treatment: Success rates approach normal -- 30-45% per transfer
- Thin endometrium (6-7 mm): Reduced success -- 15-25% per transfer
- Very thin endometrium (<6 mm): Poor prognosis -- <10% per transfer
Key Takeaway
IVF can be an option for Asherman's patients, but endometrial quality is the critical limiting factor. Optimising the cavity through surgery and endometrial preparation must come before IVF.
Costs in India
Diagnostic Costs
| Investigation | Approximate Cost |
|---|---|
| Transvaginal Ultrasound | Rs 1,000-3,000 |
| Saline Sonohysterography (SIS) | Rs 2,000-5,000 |
| HSG (Hysterosalpingography) | Rs 3,000-8,000 |
| Diagnostic Hysteroscopy | Rs 10,000-30,000 |
| MRI Pelvis | Rs 5,000-15,000 |
| TB-PCR on Endometrial Biopsy | Rs 2,000-8,000 |
| GeneXpert (TB) | Rs 3,000-5,000 |
Treatment Costs
| Procedure | Approximate Cost |
|---|---|
| Hysteroscopic Adhesiolysis (mild) | Rs 30,000-60,000 |
| Hysteroscopic Adhesiolysis (moderate-severe) | Rs 60,000-1,50,000 |
| Second-look Hysteroscopy | Rs 20,000-50,000 |
| Intrauterine Balloon / IUD | Rs 2,000-10,000 |
| Hyaluronic Acid Gel (per application) | Rs 5,000-15,000 |
| Oestrogen Therapy (4-8 weeks course) | Rs 500-2,000 |
| Anti-tubercular Treatment (ATT, 6-9 months) | Rs 5,000-15,000 (often subsidised) |
| IVF Cycle (if needed) | Rs 1,50,000-3,00,000 |
Total Estimated Cost by Scenario
| Scenario | Estimated Total Cost |
|---|---|
| Mild Asherman's: single adhesiolysis + follow-up | Rs 50,000-1,00,000 |
| Moderate Asherman's: 2 procedures + adjunctive therapy | Rs 1,00,000-2,50,000 |
| Severe Asherman's: multiple procedures + IVF | Rs 3,00,000-6,00,000 |
| TB-related: ATT + adhesiolysis + potential IVF | Rs 2,50,000-5,00,000 |
Info
Government hospitals and teaching institutions (AIIMS, PGI Chandigarh, JIPMER, KEM Mumbai, Safdarjung Hospital) offer hysteroscopic procedures at significantly lower costs. Some states provide subsidised fertility treatment under government schemes. Anti-tubercular treatment is available free through the RNTCP/NTEP (National Tuberculosis Elimination Programme).
Preventing Asherman's Syndrome
Prevention is far better than cure for Asherman's syndrome. Key strategies include:
Alternatives to D&C
- Medical management of miscarriage: Misoprostol (oral or vaginal) for incomplete miscarriage can reduce the need for D&C. The WHO recommends medical management as first-line for many miscarriages
- Expectant management: Some incomplete miscarriages resolve spontaneously within 2 weeks
- Hysteroscopic evacuation: If surgical intervention is needed, hysteroscopic removal of retained products under direct vision is associated with fewer adhesions than blind curettage
Safe Surgical Practices
- Gentle curettage: When D&C is necessary, gentle technique with a suction curette reduces endometrial damage
- Ultrasound guidance: Performing D&C under ultrasound guidance helps avoid excessive scraping
- Avoiding repeated procedures: If a second D&C is being considered, discuss the risk of adhesions with your doctor
- Post-procedure oestrogen: Some specialists prescribe prophylactic oestrogen after D&C to promote endometrial healing
TB Prevention
- BCG vaccination: Part of India's universal immunisation programme
- Early TB diagnosis and treatment: Prompt treatment of pulmonary TB reduces the risk of haematogenous spread to the genital tract
- Awareness: Young women with a family history of TB or personal TB exposure should be aware of the link between TB and fertility
Key Takeaway
The most effective prevention strategy is avoiding unnecessary D&C. If you have had a miscarriage, discuss medical management as an alternative to surgical evacuation with your doctor.
Frequently Asked Questions
Can Asherman's syndrome be cured completely?
Is Asherman's syndrome the same as a thin endometrium?
Can I conceive naturally after treatment for Asherman's syndrome?
How long after adhesiolysis should I wait to conceive?
Is Asherman's syndrome related to D&C? Could my miscarriage management have caused it?
Should I be tested for genital TB?
Can Asherman's syndrome cause infertility even if I have regular periods?
What if my adhesions keep coming back after surgery?
Sources & Citations
- **Yu D, Wong YM, Cheong Y, Xia E, Li TC.** "Asherman syndrome -- one century later." *Fertility and Sterility*, 2008; 89(4): 759-779. Comprehensive review of Asherman's syndrome pathophysiology, classification, and treatment. Source
- **AAGL Practice Report.** "Practice Guidelines for Management of Intrauterine Synechiae." *Journal of Minimally Invasive Gynecology*, 2010; 17(1): 1-7. Evidence-based guidelines for diagnosis and management of intrauterine adhesions. Source
- **Deans R, Abbott J.** "Review of Intrauterine Adhesions." *Journal of Minimally Invasive Gynecology*, 2010; 17(5): 555-569. Systematic review of aetiology, diagnosis, and treatment outcomes. Source
- **March CM.** "Asherman's Syndrome." *Seminars in Reproductive Medicine*, 2011; 29(2): 83-94. Expert review of the pathogenesis, clinical features, and management of intrauterine adhesions. Source
- **Sharma JB, Roy KK, Pushparaj M, et al.** "Genital tuberculosis: an important cause of Asherman's syndrome in India." *Archives of Gynecology and Obstetrics*, 2008; 277(1): 37-41. Indian study highlighting the role of genital TB in intrauterine adhesion formation. Source
- **FOGSI (Federation of Obstetric and Gynaecological Societies of India).** "FOGSI Good Clinical Practice Recommendations on Genital Tuberculosis and Infertility." 2022. Indian practice recommendations for managing genital TB in the context of infertility. Source
- **Hooker AB, Lemmers M, Thurkow AL, et al.** "Systematic review and meta-analysis of intrauterine adhesions after miscarriage: prevalence, risk factors and long-term reproductive outcome." *Human Reproduction Update*, 2014; 20(2): 262-278. Meta-analysis of post-miscarriage adhesion rates and fertility outcomes. Source
- **Salazar CA, Isaacson K, Morris S.** "A comprehensive review of Asherman's syndrome: causes, symptoms, and treatment options." *Current Opinion in Obstetrics and Gynecology*, 2017; 29(4): 249-256. Contemporary review of treatment approaches and outcomes. Source
- **Gupta S, Sharma JB, Mittal S.** "The impact of tuberculosis on female fertility in India." *Indian Journal of Medical Research*, 2012; 135(1): 27-30. Review of the epidemiology and impact of genital TB on fertility in Indian women. Source
- **Johary J, Xue M, Zhu X, Xu D, Velu PP.** "Efficacy of estrogen therapy in patients with intrauterine adhesions: systematic review." *Journal of Minimally Invasive Gynecology*, 2014; 21(1): 44-54. Systematic review of oestrogen supplementation in post-adhesiolysis management. Source